NASDAQ : KLRA

Kailera Therapeutics, Inc. — Financial statements

Healthcare · Biotechnology · United States

Last price 12.67 USD (Oct 30, 2026, 2:47 PM EDT) · Market cap 1.64B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Financial statements

Income statement

Fiscal year January - December; amounts in USD.

TTMFY2025FY2024
Selling, General & Admin61.87M49.23M14.06M
Research & Development251.40M109.11M10.46M
Operating Expenses313.26M158.34M24.52M
Operating Income-313.26M-158.34M-24.52M
Interest & Investment Income22.96M11.05M3.76M
Other Non Operating Income (Expenses)-1.89M-1.66M12.29M
EBT Excluding Unusual Items-292.20M-148.96M-8.46M
Pretax Income-292.20M-148.96M-329.57M
Net Income-292.20M-148.96M-329.57M
Net Income to Common-292.20M-148.96M-329.57M
Shares Outstanding (Basic)129.62M19.05K
Shares Outstanding (Diluted)129.62M19.05K
EPS (Basic)-2.25-7,819.98
EPS (Diluted)-2.25-7,819.98
Free Cash Flow-223.70M-122.30M-185.35M
Free Cash Flow Per Share-1.73-6,420.52
EBITDA-312.88M-158.03M-24.44M
D&A For EBITDA387.00K310.00K79.50K
EBIT-313.26M-158.34M-24.52M

Balance sheet

Fiscal year January - December; amounts in USD.

TTMFY2025FY2024
Cash & Equivalents130.30M160.27M175.18M
Short-Term Investments786.44M385.79M
Cash & Short-Term Investments916.74M546.06M175.18M
Other Receivables6.11M2.73M
Receivables6.11M2.73M
Prepaid Expenses5.92M7.52M2.09M
Other Current Assets395.00K1.23M343.00K
Total Current Assets929.17M557.54M177.61M
Property, Plant & Equipment11.65M12.42M680.00K
Long-Term Investments255.08M106.67M
Long-Term Deferred Charges2.60M154.00K
Other Long-Term Assets15.52M13.07M
Total Assets1.21B692.29M178.44M
Accounts Payable19.20M7.53M2.01M
Accrued Expenses62.68M36.92M2.23M
Current Portion of Leases1.05M1.04M509.00K
Other Current Liabilities721.00K916.00K2.16M
Total Current Liabilities83.65M46.41M6.91M
Long-Term Leases9.17M9.71M
Other Long-Term Liabilities135.00K270.00K
Total Liabilities92.95M56.39M6.91M
Additional Paid-In Capital1.68B11.98M941.00K
Retained Earnings-558.84M-368.67M-219.71M
Comprehensive Income & Other-1.79M229.00K
Total Common Equity1.12B-356.46M-218.77M
Shareholders' Equity1.12B635.91M171.53M
Total Liabilities & Equity1.21B692.29M178.44M
Total Debt10.22M10.75M509.00K
Net Cash (Debt)1.16B641.98M174.67M
Net Cash Per Share8.9633,703.01
Filing Date Shares Outstanding129.64M19.05K
Total Common Shares Outstanding129.62M19.05K
Working Capital845.52M511.13M170.70M
Book Value Per Share8.63-18,713.67
Tangible Book Value1.12B-356.46M-218.77M
Tangible Book Value Per Share8.63-18,713.67
Machinery1.49M262.00K
Leasehold Improvements562.00K

Cash flow statement

Fiscal year January - December; amounts in USD.

TTMFY2025FY2024
Net Income-292.20M-148.96M-329.57M
Depreciation & Amortization387.00K310.00K79.50K
Loss (Gain) From Sale of Investments-3.62M-1.73M
Stock-Based Compensation20.07M10.94M1.41M
Other Operating Activities3.14M2.44M139.50M
Change in Accounts Payable16.73M4.69M3.01M
Change in Other Net Operating Assets33.88M12.09M612.00K
Operating Cash Flow-221.62M-120.21M-184.95M
Capital Expenditures-2.09M-2.09M-393.00K
Investment in Securities-910.07M-490.51M
Investing Cash Flow-912.16M-492.60M-393.00K
Long-Term Debt Issued100.00M
Net Debt Issued (Repaid)100.00M
Issuance of Common Stock669.02M100.00K
Other Financing Activities-5.19M-315.00K
Financing Cash Flow1.16B598.66M448.11M
Net Cash Flow28.93M-14.15M262.77M
Free Cash Flow-223.70M-122.30M-185.35M
Free Cash Flow Per Share-1.73-6,420.52
Levered Free Cash Flow-59.89M
Unlevered Free Cash Flow-59.89M
Change in Working Capital50.61M16.78M3.62M

Ratios

Fiscal year January - December; amounts in USD.

TTMFY2025FY2024
Market Capitalization1.58B
Enterprise Value421.35M
Debt / Equity Ratio0.010.020.00
Net Debt / Equity Ratio-1.04-1.01-1.02
Net Debt / EBITDA Ratio3.714.067.15
Net Debt / FCF Ratio5.195.250.94
Quick Ratio11.0311.8325.35
Current Ratio11.1112.0225.70
Return on Equity (ROE)-36.90%
Return on Assets (ROA)-22.73%
Return on Capital Employed (ROCE)-27.80%-24.50%-14.30%